SK bioscience began its domestic supply of Novavax’s updated COVID-19 vaccine, which targets the XBB.1.5 variant, Dec. 18, as part of the country’s effort to provide a wider range of vaccine choices in addition to mRNA-based vaccines, according to the vaccine maker, Sunday.

SK bioscience exclusively distributes Novavax’s updated vaccine in Korea. The Ministry of Food and Drug Safety granted emergency use authorization on Nov. 29 for the product, its first approval in Asia, and the fourth globally.

Its CEO Ahn Jae-yong encouraged vaccinations by receiving the shot at a clinic near company headquarters in Seongnam, Gyeonggi Province, Dec. 18.